



# Inventaire et analyse des essais contrôlés concernant les applications mobiles de prise en charge des troubles de l'usage : une revue systématique

Bibi Rubaab Bahadoor-Giuggia

## ► To cite this version:

Bibi Rubaab Bahadoor-Giuggia. Inventaire et analyse des essais contrôlés concernant les applications mobiles de prise en charge des troubles de l'usage : une revue systématique. Médecine humaine et pathologie. 2019. dumas-02500032

**HAL Id: dumas-02500032**

**<https://dumas.ccsd.cnrs.fr/dumas-02500032>**

Submitted on 5 Mar 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



U.F.R DES SCIENCES MEDICALES

Thèse pour l'obtention du

**DIPLÔME D'ÉTAT DE DOCTEUR EN MÉDECINE**

**Présentée et soutenue publiquement le 05 novembre 2019**

**Par Rubaab BAHADOOR-GIUGGIA**

**Née le 20 octobre 1988 à Port-Louis (Ile Maurice)**

**Inventaire et analyse des essais contrôlés concernant les  
applications mobiles de prise en charge des troubles de l'usage :  
une revue systématique**

**Directeur de thèse**

**Monsieur le Professeur Marc Auriacombe**

**Président du jury**

**Monsieur le Professeur Pierre Philip**

**Membres du jury**

**Monsieur le Professeur William Durieux  
Monsieur le Docteur David Chevillot**

**Rapporteur de thèse**

**Monsieur le Docteur Jean-Arthur Micoulaud  
Franchi**

## **Remerciements**

### **A Monsieur le Professeur Pierre PHILIP**

Vous me faites l'honneur de présider le jury de ma thèse, recevez mes sincères remerciements et le témoignage de ma profonde considération.

### **A Monsieur le Professeur Marc AURIACOMBE,**

Je vous remercie de m'avoir guidé tout au long de cette thèse, de m'avoir apporté toute la disponibilité, les connaissances et le soutien dont j'avais besoin. Veuillez recevoir l'expression de ma profonde gratitude.

### **A Monsieur le Professeur William DURIEUX**

Vous me faites l'honneur de juger ce travail, soyez assuré de ma reconnaissance et de mon profond respect.

### **A Monsieur le Docteur Jean-Arthur MICOULAUD FRANCHI**

Vous avez accepté d'évaluer ce travail en qualité de rapporteur et de me faire l'honneur de siéger dans mon jury. Veuillez recevoir l'expression de ma respectueuse gratitude

### **A Monsieur le Docteur David CHEVILLOT,**

Merci d'avoir accepté de faire partie du jury, de m'avoir accompagné avec bienveillance pendant mon stage SASPAS. Je vous remercie pour tout ce que vous m'avez transmis et de la confiance qui m'a été accordée.

**A ma mère**, pour tout ce que tu nous as transmis, ta foi, ton soutien et ta présence. C'est grâce à toi et papa que j'en suis là aujourd'hui.

**À ma moitié**, ton soutien a été sans faille depuis le début de ces longues études, merci pour ta patience, ton amour et les beaux enfants que tu m'as donné. A nous, pour le meilleur et pour le pire. A ma petite princesse, qui nous comble de bonheur au quotidien. A mon petit prince, j'ai tellement hâte de te tenir dans mes bras.

**A mon frère, ma sœur** et mon frère de cœur, pour votre contribution à l'aboutissement de ce travail, votre soutien et votre bienveillance, je ne vous remercierai jamais assez.

**A mes relecteurs**, qui se reconnaîtront, merci de votre contribution dans l'aboutissement de ce travail et de vos précieux conseils.

**A mes amis**, d'ici et d'ailleurs, merci pour les bons moments passés et les nombreux à venir.

**A tous les médecins, équipes soignantes, secrétaires** que j'ai pu rencontrer durant mon internat et mes remplacements, je vous remercie de la confiance que vous m'avez accordée.

A tous ceux qui ont cru en moi et qui m'ont soutenu depuis le début, merci pour votre confiance.

*A la mémoire de mon père.*

## **Table of contents**

<b>ABBREVIATIONS.....</b>	<b>6</b>
<b>SYNOPSIS.....</b>	<b>7</b>
<b>1 INTRODUCTION.....</b>	<b>11</b>
<b>2 METHOD.....</b>	<b>12</b>
<b>2.1 RESOURCE IDENTIFICATION.....</b>	<b>12</b>
<b>2.2 SELECTION OF STUDIES .....</b>	<b>12</b>
<b>2.3 DATA EXTRACTION AND SYNTHESIS .....</b>	<b>13</b>
<b>3 RESULTS.....</b>	<b>13</b>
<b>3.1 STUDY SELECTION .....</b>	<b>13</b>
<b>3.2 TOBACCO ADDICTION APPLICATIONS .....</b>	<b>14</b>
3.2.1 <i>Characteristics of studies (Table 3-4).....</i>	<i>14</i>
3.2.2 <i>Effectiveness of applications (Table 3) .....</i>	<i>14</i>
3.2.3 <i>Functionalities of applications (Table 4).....</i>	<i>14</i>
3.2.4 <i>Impact of interventions on craving (Table 3).....</i>	<i>15</i>
3.2.5 <i>Methodological quality of studies - risk of bias (Table 5) .....</i>	<i>15</i>
<b>3.3 ALCOHOL ADDICTION APPLICATIONS .....</b>	<b>15</b>
3.3.1 <i>Characteristics of studies (Table 3-4).....</i>	<i>15</i>
3.3.2 <i>Effectiveness of applications (Table 3) .....</i>	<i>15</i>
3.3.3 <i>Functionalities of the applications (Table 4) .....</i>	<i>16</i>
3.3.4 <i>Impact of interventions on craving (Table 3).....</i>	<i>16</i>
3.3.5 <i>Methodological quality of studies - risk of bias (Table 5) .....</i>	<i>16</i>
<b>3.4 ILLEGAL SUBSTANCES ADDICTION APPLICATION .....</b>	<b>16</b>
3.4.1 <i>Characteristics of study (Table 3-4).....</i>	<i>16</i>
3.4.2 <i>Effectiveness of application (Table 3).....</i>	<i>16</i>
3.4.3 <i>Functionalities of the application (Table 4).....</i>	<i>17</i>
3.4.4 <i>Impact of interventions on craving (Table 3).....</i>	<i>17</i>
3.4.5 <i>Methodological quality of study - risk of bias (Table 5).....</i>	<i>17</i>
<b>3.5 BINGE EATING ADDICTION APPLICATION.....</b>	<b>17</b>
3.5.1 <i>Characteristics of study (Table 3-4).....</i>	<i>17</i>
3.5.2 <i>Effectiveness of application (Table 3).....</i>	<i>17</i>
3.5.3 <i>Functionalities of the application (Table 4).....</i>	<i>17</i>
3.5.4 <i>Impact of interventions on craving (Table 3).....</i>	<i>18</i>
3.5.5 <i>Methodological quality of study - risk of bias (Table 5).....</i>	<i>18</i>
<b>4 DISCUSSION .....</b>	<b>18</b>
<b>4.1 SYNTHESIS OF THE MAIN RESULTS .....</b>	<b>18</b>
<b>4.2 CRITICAL ANALYSIS OF EFFECTIVE APPLICATIONS .....</b>	<b>18</b>
<b>4.3 CRITICAL ANALYSIS OF INEFFECTIVE APPLICATIONS .....</b>	<b>19</b>
<b>4.4 CRAVING MANAGEMENT .....</b>	<b>20</b>
<b>4.5 VALIDITY OF RESULTS .....</b>	<b>20</b>
<b>4.6 PROSPECTS OF IMPROVEMENT OF APPLICATIONS .....</b>	<b>21</b>
<b>4.7 LIMITATIONS.....</b>	<b>21</b>
<b>5 CONCLUSION.....</b>	<b>21</b>
<b>6 REFERENCES:.....</b>	<b>22</b>

## **Abbreviations**

AUD: Alcohol Use Disorder

AUDIT: Alcohol Use Disorder Test

BAC: Blood Alcohol Concentration

BED: Binge eating disorder

CBT: cognitive behavior therapy

DDQ: Daily Drinking Questionnaire

DSM: Diagnostic and Statistical Manual of Mental Disorders

EDE-Q: Eating Disorder Examination-Questionnaire

HIV: Human Immunodeficiency Virus

HSI: Heaviness Smoking Index

ICD: International Classification of Diseases

m-Health: mobile health

SUD: Substance Use Disorder

## **SYNOPSIS**

Les conduites addictives sont une préoccupation majeure de santé dans la plupart des pays du monde (1). Le taux de mortalité lié aux troubles de l'usage ainsi que l'impact économique en raison de la perte du capital humain et les dépenses de santé sont considérables (2–4). L'addiction est une pathologie chronique qui est caractérisée par des rechutes à répétition, souvent amorcées par le craving (5–7). Un changement de comportement d'usage durable nécessite une prise en charge au-delà de l'arrêt de la consommation. Cependant, moins de 20% des malades ont accès à une prise en charge adaptée (8,9). La santé mobile peut améliorer la prévention, le diagnostic et la prise en charge thérapeutique des troubles de l'usage (8) en offrant l'accès à l'information médicale et un accompagnement dans les démarches de soins quel que soit le lieu, l'heure ou le contexte socio-culturel (10,11). Alors que les applications de santé se développent à un rythme effréné, peu de preuves existent sur leur efficacité (12–14).

Cette revue systématique de la littérature avait pour but de répertorier et d'analyser les essais thérapeutiques contrôlés concernant les applications mobiles, destinées à accompagner les personnes atteintes d'une consommation problématique (avec ou sans substance), qui ont été évaluées pour leur efficacité sur le changement de comportement d'usage. Secondairement, nous avons cherché à identifier les stratégies de changement de comportement utilisées dans ces applications ainsi que la prise en compte du craving.

Notre recherche sur les trois bases de données (MEDLINE, CENTRAL et PsycINFO) (Tableau 1) a permis d'identifier 22 essais contrôlés (Figure 1) qui concernaient 22 applications d'aide à l'arrêt de conduites addictives (Tableau 2). Chaque application ciblait sur un comportement addictif unique : le tabac, l'alcool, les substances illégales et les troubles du comportement alimentaire de type boulimie (15–36). Ces études, concernant 39 031 participants majeurs de 11 pays différents (aucune en France), sur une durée moyenne de 5 mois, ont été publiées entre 2014 et 2019.

Huit applications (3 pour le tabac, 4 pour l'alcool et 1 pour les substances illégales) ont montré un impact positif sur le changement de comportement d'usage par une réduction de la consommation et/ou une augmentation de l'abstinence chez des personnes ayant une sévérité variable d'addiction (16,18,19,30–35) (Tableau 3). Les groupes contrôles, dans les différents essais, étaient hétérogènes (traitements habituels/ application placebo/ absence d'intervention) (Tableau 4). Une application, prenant en charge le trouble de l'usage de l'alcool, a mis en évidence une augmentation, inexpliquée, de la fréquence de consommation (29).



La majorité des applications délivraient des informations sur les risques de consommation et les bénéfices de l'arrêt de l'usage ou proposaient une surveillance de la consommation. Certaines applications présentaient des spécificités sur leur mode d'intervention : la personnalisation des données, le mode de détection de la consommation ou la technique de gestion du craving (Tableau 4). Douze applications prenaient en charge le craving en informant sur ce symptôme ou en proposant des solutions pour le gérer (15,17,20,21,23–25,28,31–33,35). Parmi les trois applications (17,20,21) qui évaluaient l'impact de l'intervention sur le craving, deux applications ont montré une efficacité sur la réduction de l'intensité du craving ou de l'association entre le craving et la substance et par conséquent, un effet positif sur la réduction de l'usage (17,20) (Tableau 3). La qualité méthodologique des études était variable et n'avait pas de lien avec l'efficacité des interventions (Tableau 5).

Toutefois, ces résultats sont à interpréter avec prudence. De nombreuses limites ont pu être identifiées dans les études concernant les applications jugées efficaces, telles que, le manque de preuve sur le maintien du changement de comportement d'usage à terme de l'étude (16), des défauts de randomisation (19,32), l'hétérogénéité entre les groupes d'études (18,19) ou le manque de puissance des essais (19,31,35). Seule une application sur le trouble de l'usage de l'alcool a été testée sur une durée suffisamment longue (12 mois) pour prédire l'impact durable sur la consommation (31,33). A l'inverse, certaines applications, considérées inefficaces par rapport aux comparateurs, ont montré une baisse non négligeable de la consommation (15) ou un impact positif sur le craving (17,20).

Plusieurs pistes seront à considérer lors du développement et de l'évaluation des applications futurs. Les interventions de santé mobile doivent continuer à cibler les mécanismes psychologiques de changement de comportement d'usage, tels que l'auto-efficacité en impliquant le patient activement dans sa prise en charge. La prise en compte systématique du craving, indépendamment du type d'addiction, est primordial pour prévenir les risques de rechutes à long terme. Enfin, des études plus rigoureuses, dans des contextes divers et de durée suffisamment longue, sont nécessaires pour mieux comprendre les limites des applications mobiles et les profils de patients (niveaux de sévérité) qui seraient susceptibles d'être les plus réceptifs à ce mode d'intervention.

Les études sur les applications mobiles d'aide à l'arrêt des conduites addictives sont récentes. Seules 9 de ces applications sont disponibles en France (18–20,23,24,26,27,34,36). Treize études concernant des applications de santé en addictologie sont enregistrées dans la base de données Clinical Trial (Tableau 6). A ce jour, peu de données probantes sur l'efficacité existent pour pouvoir recommander ces applications dans la pratique courante.

**Inventory and analysis of controlled trials of mobile phone applications targeting substance use disorders: a systematic review.**

Rubaab Bahadoor (1, 2), Fuschia Serre (1, 2,3), Marc Auriacombe (1, 2, 3, 4)

- (1) Université de Bordeaux, Bordeaux, France.
- (2) Équipe phénoménologie et déterminants des comportements appétitifs, Sanpsy CNRS USR 3413, Université de Bordeaux, Bordeaux, France.
- (3) Pôle addictologie et filière régionale, CH Charles Perrens et CHU de Bordeaux, Bordeaux, France.
- (4) Center for studies of addiction, department of psychiatry, Perelman school of medicine, university of Pennsylvania, Philadelphia, PA, USA

**Corresponding author:**

Marc Auriacombe

E-mail : marc.auriacombe@u-bordeaux.fr

Pôle addictologie, CHCP, 121 rue de la Béchade, 33076 Bordeaux Cedex, France

Tel: +33 556 561 738

Fax: +33 556 561 727

Number of words text: 4956

Number of figures: 1

Number of words abstract: 243

Number of tables: 6

Declarations of interest: None

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## **Abstract**

**Background:** Less than 20% of people with addictive disorders have access to adequate treatment. Mobile health could help to improve access to care. No systematic review evaluates the effectiveness of mobile health applications.

**Objectives:** To describe controlled trials evaluating the effectiveness of smartphone applications which target substance use disorders and addictive behaviors, to understand how the application produced changes in use or behavior and the management of craving.

**Method:** A systematic review was conducted on MEDLINE, CENTRAL and PsycINFO.

**Results:** The search strategy retrieved 22 articles published between 2014 and 2019 corresponding to 22 applications targeting tobacco, alcohol, illegal substance and binge eating disorder. The control group had access to usual treatments or a placebo-application or no treatment. Eight applications showed reduced use. Most of the applications informed about the risks of use and gave suggestions for monitoring use. Twelve applications managed craving.

**Discussion:** The results of the studies are limited by some important biases, notably heterogeneity in the control groups. The duration of the studies was too short to be able to predict sustainable results. The positive impact on craving seems to be related to a reduction in use behavior.

**Conclusion:** There is currently insufficient evidence to recommend the use of these smartphone applications in clinical practice. Craving should be considered more systematically, irrespective of the type of substance or behavior, to prevent relapse. Longer-term assessments will be needed to be able to accurately indicate the sustainable change in behavior or use.

**Key words:** substance use disorder, mHealth, efficacy, mobile applications, systematic review.

# 1 INTRODUCTION

Substance use disorder (SUD) or behavioral addiction, is a major public health concern since it affects 10-15% of the world population (1). Over the last few years, the worldwide prevalence of legal and illegal substance use has remained globally stable. Even if European countries have the highest prevalence of alcohol and tobacco consumption, a decrease in use has been observed over the past decade (4,37). However, the health burden related to SUDs has a substantial economic impact due to the loss of human capital and the significant costs in health care. The mortality rate in the world is alarming: more than 7 million of deaths per year for tobacco, more than 3 million for alcohol and 450,000 for illegal substances (2–4).

Addiction is a chronic disorder which persists beyond abstinence. More than the withdrawal symptoms, craving is considered to be major contributor to repeated relapses (5–7). Craving is listed as one of the diagnostic criteria in the latest DSM 5, placing it as a main symptom of addiction and a legitimate target for treatment (38). It is estimated that overall less than 20% of people with an addictive disorder have access to adequate treatment and this is true across countries (2,8,9).

Mobile health (mHealth) may help to reduce this “treatment gap” by improving early diagnosis and access to treatment (8,9). It has been defined by the World Health Organization as any medical intervention based on mobile devices (39). Patients with chronic diseases are particularly concerned, both in developed and developing countries, where the use of mobile services is increasing. It is also a means to overcome social and territorial disparities in health (40,41). The digitalization of healthcare services has improved access to information, professional support and medical assistance due to its asynchronous means of communication that abolishes barriers such as travelling time and costs and schedule conflicts with healthcare professionals (10,11).

mHealth can also contribute to raise awareness among young substance users who consider themselves in good health, while this population is very much affected by risky behaviors (42–44). In France, only 12% of teenagers have never experienced tobacco, alcohol or cannabis; revealing a high accessibility of these substances (45) and this is true also in Europe, North America and Australia (46–48). Smartphones, as an autonomous tool, may be a promising new direction to improve the commitment of young adults to care and improving self-efficacy and empowerment (15).

In clinical practice, health applications may offer a complementary approach to usual direct contact care. The combined application of cognitive behavioral therapy (CBT) with

smartphone applications could increase access to effective interventions (49). Immediate intervention through these applications can enhance therapeutic effectiveness, consolidate and maintain behavioral change on a long term basis (50), thus, helping the patient to be independent without being isolated from professional support.

While more than 300,000 health applications currently exist (51), including hundreds of ‘cessation support’ applications, few of them have been clinically tested before being put on the market (10,52). The majority of these applications have no proof of validity (12,53,54). Some applications even encourage substance use, implicitly or explicitly (13,52,54). Yet, studies suggest that mobile applications can positively influence our health behavior (55,56). Some web-based or instant messaging interventions have demonstrated short- to mid-term effectiveness in reducing use (57,58). To date, no systematic review has evaluated the effectiveness of mobile applications for the treatment of addictive disorders (12–14). The aim of this study was to identify and describe controlled treatment trials on mobile health applications which support behavior change among users with problematic behaviors or substance uses by the reduction of use or abstinence. Secondly, we aimed to understand the change strategies employed and how craving was managed.

## **2 METHOD**

This systematic literature review was based on the « Preferred Reporting Items for Systematic Reviews and Meta-analyses » (PRISMA) recommendations (59).

### **2.1 Resource identification**

Keywords were defined around 4 criteria (mobile applications, use disorder, effectiveness, excluding web-based interventions) and linked by Boolean operators to generate the following MESH equation: *((smartphone app\* OR mobile app\*)) AND ((substance use disorder OR addict\* OR addictive behavior OR cessation OR recovery OR craving OR alcohol OR smok\* OR tobacco OR cannabis OR marijuana OR heroin OR cocaine OR opioid OR gambl\* OR binge eating OR porn)) AND ((efficacy OR effectiveness OR impact OR validity)) NOT ((web-based intervention OR Internet)).*

Literature searches were performed using MEDLINE, Cochrane central register of controlled trial (CENTRAL) and PsycINFO, up to 1<sup>st</sup> July 2019.

### **2.2 Selection of studies**

Studies were included if they met the following criteria: controlled trials concerning addictive disorders (substance/behavior), mobile application-based interventions, assessing the

effectiveness or impact of those applications upon use. The research was limited to English and French articles that were published after 2008 which corresponds to the year of first release of health applications.

Age, sex or nationality of the sample population were not included in the selection criteria. Articles doing a descriptive review of mobile applications, study protocols with no results on efficacy, and literature reviews were excluded.

The articles were first screened by their title and abstract. If relevant, full-text articles were read entirely for a second level selection. Database access and reference management were done by the Endnote X6 software.

### **2.3 Data extraction and synthesis**

Each selected paper was screened for relevant information such as whether the application treated one or more addictions, its functionalities, the target population, the randomization, the characteristics of the control group(s) and the impact on use and/or craving. The quality of the study was evaluated by the JADAD score (60); a good methodological quality was defined by a score above 3/5.

## **3 RESULTS**

### **3.1 Study selection**

The initial search found 1713 articles. After screening by titles and abstracts, 34 articles were retained and thoroughly reviewed. Twenty-two controlled studies met our eligibility criteria. The selection steps are shown in Figure 1. The 22 selected articles concerning 22 applications (Table 2) focused on: tobacco (12 articles) (15–26), alcohol (8 articles) (27–34), illegal substances (1 article) (35) and binge eating disorder (BED) (1 article) (36). The 'A-CHESS' and 'SmartQuit' (version 1.0 and 2.1) applications were each studied by two different teams (17,24,31,33). One study evaluated two alcohol cessation applications ('Promillekoll' and 'PartyPlanner') (29). No application was dedicated to multiple addictions.

The majority of studies were published since 2017 ( $n = 18$ ) and a minority ( $n = 4$ ) in 2014 and 2015, no studies were published before. The detailed analysis of each study is presented in Tables 3 to 5. A total of 39,031 participants were included in the studies (tobacco: 34,174; alcohol: 4,716; illegal substances: 75; BED: 66) whose duration ranged from 1 to 12 months (average 5 months). The studies were conducted in 11 different countries (Table 3). Two studies included participants aged 16 and over (25,34) and the other studies included adults.

## 3.2 Tobacco addiction applications

### 3.2.1 *Characteristics of studies* (Table 3-4)

One study targeted users aged 19-29 years (15). One application was specifically intended to support pregnant women (26) and another one for aboriginal Australian population (25). The level of severity of addiction was variable in the studies. Two studies included people with high severity (Heaviness smoking index (HSI)  $\geq 5$ , Fagerström  $\geq 7$ ) (17,19) and two others, of medium severity (HSI= 3, Fagerström= 5) (24,26).

One application was compared to a self-help guide with similar contents to the application (15), three applications were compared to group therapy or brief intervention (21,22,24) and two other control groups did not have access to any intervention (19,25). Other studies compared the active application to a placebo version of the application, mainly for informational or monitoring purposes (16–18,20,23,26).

### 3.2.2 *Effectiveness of applications* (Table 3)

The evaluation criteria of the studies were self-reported abstinence (15–19,21,23,26) or biologically verified abstinence (expired /urinary level of carbon monoxide (CO)) (20,22,24,25) or self-reported reduction in use (19,26).

The rate of abstinence for the ‘Quit Advisor Plus’ application was at 28.5 % at 1 month compared to 10.2% at 6-month follow-up. Nevertheless, the overall quit rate for ‘Quit Advisor Plus’ (16) and for the remaining 2214 participants of ‘SmokeFree’ (18), who had variable nicotine dependence levels, was significantly higher compared to the placebo application, at 6 months and 3 months, respectively. The ‘SmokeBeat’ application (19) showed a significant reduction, at 1 month, in the number of cigarettes per day, among adult smokers with severe addiction (Fagerström score: 12.50 and 19.95 for interventional group and control group, respectively) compared to five other applications (15,20,22,24,26). The other studies did not specify the reduction of use (16–18,21,23,25).

### 3.2.3 *Functionalities of applications* (Table 4)

The main functions of the applications were information on the risks of tobacco use, the benefits of abstinence, the different modes of cessation and monitoring of use, financial savings and health gains due to quitting. Some applications had special features, such as personalization of data (16,17,23,24), the particular modes of detecting tobacco use (19,22) or specific craving management techniques (17,18,20,21,24).

### 3.2.4 *Impact of interventions on craving* (Table 3)

Among the eight applications which managed craving (15,17,18,20,21,23–25), three of them (17,20,21) evaluated the effectiveness of the intervention on this symptom. Unlike 'PhoS' (21), 'SmartQuit 1.0' (17) showed a positive impact on craving with a higher quit rate and 'Craving to Quit' (20), a reduction in craving intensity as well as a decrease in the association between craving and tobacco use.

### 3.2.5 *Methodological quality of studies - risk of bias* (Table 5)

Two studies had low methodological quality (JADAD score <3) (19,22) due to a non-optimal randomization (19) or the lack of description of randomization and double-blinding (22). Five studies were single-blinded (18,19,23,24,26).

## 3.3 **Alcohol addiction applications**

### 3.3.1 *Characteristics of studies* (Table 3-4)

Three studies aimed university students (29,30) or users aged 16-25 years (34)) engaged in hazardous drinking (Alcohol Use Disorder Test (AUDIT) score  $\geq 6$  for women,  $\geq 8$  for men,  $>4$  drinks per event) (30,34). Other studies included users with alcohol use disorder (AUD) according to the DSM IV (31,33) and 5 (32) criteria or AUDIT score  $>12$  (27,28). Two studies recruited patients with AUD who were discharged from residential treatment programs (31,33).

Two applications were compared to the usual CBT program or brief intervention (31–33) ), and one application was compared to a placebo version which was non-customizable and for information purposes only (28). One control group had delayed access, at 1 month, to the application (34) and three others had no intervention (31–33).

### 3.3.2 *Effectiveness of applications* (Table 3)

The main outcome was alcohol reduction in quantity and/or frequency, either self-reported (27,28,31–33) or evaluated by the AUDIT score and/or the daily drinking questionnaire (DDQ) (28–30,34). Complete alcohol cessation was sought in three studies (31–33).

Three studies, concerning the two applications 'A-CHESS' (31,33) and 'LBMI-A' (32) found a significant reduction in use as well as an increase in abstinence, among patients who were diagnosed with AUD, at 12 months and 6 weeks, respectively. The users of 'A-CHESS' application had also a better adherence to outpatient addiction treatment. A causal relationship between the use of 'A-CHESS' and the decrease in risky drinking days was found (31). The



‘TeleCoach’ (30) application showed a significant decrease in the frequency of use, without any impact on the quantity, at 3-month follow-up while ‘Ray’s Night Out’ (34) showed a reduction in the quantity of alcohol use only at 1 month assessment. The ‘Promillekoll’ application that estimated the blood alcohol concentration (BAC), showed a higher frequency of alcohol use (29). Compared to the control group, no change in drinking behavior were reported in the other studies (27–29).

### 3.3.3 *Functionalities of the applications* (Table 4)

Most of the applications informed about the consequences of risky drinking and monitored the number of drinks. Three applications estimated the BAC (27,29). One application used cognitive bias retraining by alcohol eviction games to review the user’s approach to alcohol use (28). Three applications prevented situations of high risk of relapse by identifying craving in real time (30–33). The self-determination theory which aimed at developing competency, relatedness and autonomy was used in one application (31,33).

### 3.3.4 *Impact of interventions on craving* (Table 3)

Although three applications managed craving, the effectiveness on its reduction was not sought in the corresponding studies: ‘A-CHESS’ (31,33), ‘LBMI-A’ (32) and ‘TeleCoach’ (30).

### 3.3.5 *Methodological quality of studies - risk of bias* (Table 5)

Five studies were of good methodological quality (JADAD score  $\geq 3$ ) (29–31,33,34). One study was not randomized (32). None of the studies were double-blinded.

## 3.4 **Illegal substances addiction application**

### 3.4.1 *Characteristics of study* (Table 3-4)

Only one study concerning the ‘S-Health’ application was identified (35). The participants were users of illegal substances (ex: heroin, amphetamines ...) with methadone treatment for opioid addiction.

The control group had access to a placebo version of the application that only provided information on use by instant messages.

### 3.4.2 *Effectiveness of application* (Table 3)

The number of days of use was self-reported daily and a multi-drug urine test was performed weekly by a clinician. A significant decrease in the number of days of use was observed in the

interventional group. However, the positivity of the urine test was not statistically different between the two groups.

#### 3.4.3 *Functionalities of the application* (Table 4)

Multiple surveys were conducted daily, systematically or upon request, about the expression and the context in which craving occurred, the affects and the responses. The application also informed about risks reduction of HIV risk behavior and provided educational materials by text messages.

#### 3.4.4 *Impact of interventions on craving* (Table 3)

Even if the application dealt with craving, the impact of the intervention on this symptom was not sought, only substance use was reported.

#### 3.4.5 *Methodological quality of study - risk of bias* (Table 5)

This study had a low methodological quality (JADAD score = 1). The method of randomization was incorrect as the distribution of participants between the two groups was uneven. The study was not conducted in double-blind condition.

### **3.5 Binge eating addiction application**

#### 3.5.1 *Characteristics of study* (Table 3-4)

Only one study concerning the ‘Noom monitor’ application was found (36). Participants were eligible if they met the diagnostic criteria of bulimia nervosa or binge eating disorder according to the DSM 5 or DSM IV with once weekly binge eating and/or purging.

The combined use of the application to behavioral cognitive therapy (BCT) was compared to BCT alone.

#### 3.5.2 *Effectiveness of application* (Table 3)

The change in eating disorder behavior, with or without compensatory behaviors was evaluated by the Eating Disorder Examination Questionnaire (EDE-Q). No significant difference was found in the decrease of binge eating episodes or compensatory behaviors in both arms.

#### 3.5.3 *Functionalities of the application* (Table 4)

The application served as a self-monitoring tool to record activities (physical exercises, meals/snacks, compensatory behaviors, craving, weight, personal notes).

### 3.5.4 *Impact of interventions on craving* (Table 3)

The effect of the intervention on craving was not evaluated in this study.

### 3.5.5 *Methodological quality of study - risk of bias* (Table 5)

The study had a good methodological quality (JADAD score = 3). Double-blind was maintained during randomization till the first session of care with a therapist.

## **4 DISCUSSION**

### **4.1 Synthesis of the main results**

The aim of this systematic review of the literature was to identify and describe published controlled trials concerning health applications which support addiction behavior change among problem users, to substance or behavior addictions. We identified 22 trials regarding 22 applications. Each application targeted a unique addiction: tobacco, alcohol, illegal substances and binge eating. The results of this review suggest that very few of these applications have shown compelling evidences of their efficacy upon abstinence or reduction of use or craving.

### **4.2 Critical analysis of effective applications**

A total of 8 applications reported results supporting effectiveness (3 for tobacco, 4 for alcohol and 1 for illegal substance use). Among the smoking addiction applications, ‘Quit Advisor Plus’ (16), ‘SmokeFree’ (18) and ‘SmokeBeat’ (19) showed significant change in use behavior compared to controls, at 6, 3 and 1 month, respectively. Even if the rate of abstinence was higher for ‘Quit Advisor Plus’, a constant decline in quit rates was observed throughout the study. The number of abstinent participants was, numerically, half as important at 6-month follow-up which implies that more than half of them relapsed (16). The two other studies had important attrition bias (18,19). The retention rates were extremely low (7,5%) for ‘SmokeFree’, despite massive recruitment, leading to inequalities between the characteristics of the study arms (18). Disparities were also found for ‘SmokeBeat’ (19), where the control group had a higher nicotine dependence level due to error in randomization, which could, partially, explain the lack of effectiveness of the intervention in this group. Both ‘SmokeFree’ (18) and ‘SmokeBeat’ (19) were conducted over a too short duration to predict sustainable results on efficacy. Furthermore, no sub-group analysis was made to determine which level of severity of addiction could be more receptive to this type of intervention.

For applications which treated AUD, ‘A-CHESS’ showed a positive impact on use behavior among diagnosed patients, during aftercare, over 12 months. Findings in both studies were consistent and a causal effect of A-CHESS to the reduction of use was reported. A better compliance to treatment was found in the intervention group. ‘A-CHESS’ was the only application whose study was conducted during aftercare which represents a crucial moment for therapeutic adherence (31,33). The impact of this application could be explained by the mechanism of behavior change based on self-efficacy and the fact that patients were encouraged to be proactive in their care by seeking social support in critical moments. The long study duration supports the effects of the intervention on a long-time basis.

The efficacy of ‘LBMI-A’ (32), ‘TeleCoach’ (30) and ‘Ray’s Night Out’ (34) was less convincing. The poor methodological quality, the short study duration as well as the lack of statistical power for ‘LBMI-A’ impaired the quality of the study and did not allow relevant conclusions to be drawn (32). As for ‘TeleCoach’ (30), the exclusive decrease in the frequency of use has no clinical value. The reduction in the quantity of use for ‘Ray’s Night Out’ (34), only at 1 month, was attributed, by the authors, to an assessment effect where an unconscious change in habits of use might occur at inclusion. No plausible argument supports the effect of those applications on behavior change.

For illegal substances, ‘S-Health’ tested on patients with opioid use disorders showed a positive impact on the reduction of use (35). However, biological verification did not correlate those results at 1-month assessment. Change in use behavior could have been overestimated by memory bias due to retrospective self-report of use and randomization bias.

### **4.3 Critical analysis of ineffective applications**

Fourteen applications (9 for tobacco (15,17,20–26), 4 for alcohol (27–29) and 1 for BED (36)) were considered to be ineffective. However, ‘Crush the crave’ targeting smoking, which did not show greater efficacy than the manual guide, had a high quit rate (230/1599). Also, 30 more participants smoked less than one pack per day while using the application (15). Several factors may have influenced these results such as the frequency of use (higher for the guide) or the on-demand solicitation of the application which may be perceived as a burden by the user. The clinical impact of these findings is substantial. Moreover, the mechanism of delivery being different, the mobile application can be more easily disseminated than a paper booklet.

The use of BAC in the 'Promillekoll' application showed an unexplained increase in alcohol use (29). The calculation of BAC so as to limit use, in various studies, has not been proven effective (27,29,34).

Several biases have been identified in the other trials making the results on efficacy difficult to interpret, such as confusion factors with the control groups (21,24,28,36) or attrition bias (19,24,28) between the two arms, the short study duration (less than 6 months) (17–19,22,26,28–30,32,35) or the low statistical power of some trials (17,19,21,24,25,30,32,34–36) which lead to an under-estimation of the results.

#### **4.4 Craving management**

Twelve applications managed craving. 'A-CHESS', which showed probative results on change in use, specifically monitored craving and proposed real-time solutions to manage this symptom (31,33). Even if, 'Craving to Quit' (20) and 'SmartQuit' (17) did not show significant effect on use, their craving management techniques seemed effective, on the short-term, on the intensity of craving, the association of craving and use or a better acceptance of the symptom which was correlated to a higher prevalence of abstinence. The lack of impact of physical activities on craving for the 'PhoS' application could be explained by the fact that both study arms received information on the benefits of physical activities prior to the test (confusion factor) (21).

The other applications did not systematically evaluate the impact of the interventions on this symptom which made it difficult to determine whether the craving management techniques, used in those applications, are really effective.

#### **4.5 Validity of results**

Two applications (out of 8) which were considered effective by the authors had poor methodological quality (19,32) due to inappropriate randomization. The JADAD score, used in this review, had certain limits. Double-blinding was not always possible between the study groups due to heterogeneous comparators (e.g., application compared to a paper booklet or no intervention). Some information could have been omitted due to volume restriction of journals. Applications which are considered effective on one population, in a particular country should be tested in other contexts before any conclusion can be made on generalizability.

#### **4.6 Prospects of improvement of applications**

More randomized controlled trials (RCTs) are required over a sufficiently longer period, minimum 12 months, and on a larger scale to be able to predict sustainable results. Information and monitoring are important features of health applications, however, the active involvement of the user (e.g. by daily missions) could be more effective in enhancing the effects of the intervention. Mobile health interventions should continue to target the psychological mechanisms implied in behavior change, such as self-efficacy. A more systematic consideration of craving by the applications should be considered. The lack of support for craving might explain the failure to maintain change in behavior observed for some applications (16,28,30). The impact of these interventions must be measured in different contexts (with or without treatment, on different severity of addiction, in various sociodemographic contexts) to better understand their limitations and the profile of patients who could be more receptive to this type of intervention.

#### **4.7 Limitations**

Some important limitations of this review are to be acknowledged. Although every effort was made to ensure that this review of the literature is comprehensive and encompasses all available literature, additional articles may have been omitted. Publication bias cannot be excluded as searches were led on only three databases. Studies on the impact of the selected applications are recent and many more are in progress. Thirteen trials concerning addiction recovery applications have been identified in the Clinical Trial database (Table 6). This systematic review will need to be updated in a few years.

### **5 CONCLUSION**

Findings suggest that smartphone applications can, effectively, contribute to behavior change and craving management in SUDs. However, to date, very few applications have been evaluated for validity and the evidences on the efficacy of mHealth addiction recovery applications are too limited to be able to recommend them as an autonomous or complementary tool for the treatment of SUDs. More rigorous RCTs including more homogeneous comparators are required, on larger scale and with longer-term evaluations so as to clarify the sustainability of the change in use behavior. Real-time interventions have immediate impact on behavior change. However, the long-term challenge is the prevention of relapse through the management of craving.

## 6 REFERENCES:

1. World Health Organization (WHO). Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva: WHO; 2009.
2. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2018. Vienna: UNODC; 2018.
3. World Health Organization (WHO). WHO report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies. Geneva: WHO; 2017.
4. World Health Organization (WHO). Global status report on alcohol and health 2018. Geneva: WHO; 2018.
5. Auriacombe M, Fatséas M. Principes de la thérapeutique et des prises en charge en addictologie. Lejoyeux M Ed Abr D'addictologie Paris Masson. 2008;62–8.
6. Auriacombe M, Serre F, Denis C, Fatséas, M. Diagnosis of addictions. H Pick H Ahmed Eds. 2018.
7. Sayette MA. The Role of Craving in Substance Use Disorders: Theoretical and Methodological Issues. *Annu Rev Clin Psychol*. 2016 Mar 28;12(1):407–33.
8. Thierry J-P, Reynaud M. e-SANTÉ ET ADDICTIONS. Addictions : La révolution de l'e-santé pour la prévention, le diagnostic et la prise en charge. [Internet]. 2019. Available from: <https://www.drogues.gouv.fr/sites/drogues.gouv.fr/files/atoms/files/rapport-e-sante-2019-num-v4.pdf>
9. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. *Bull World Health Organ*. 2004;82(11):858–66.
10. Haskins BL, Lesperance D, Gibbons P, Boudreaux ED. A systematic review of smartphone applications for smoking cessation. *Transl Behav Med*. 2017 Jun;7(2):292–9.
11. Dennison L, Morrison L, Conway G, Yardley L. Opportunities and Challenges for Smartphone Applications in Supporting Health Behavior change: Qualitative Study. *J Med Internet Res*. 2013 Apr 18;15(4):e86.
12. Thornton L, Quinn C, Birrell L, Guillaumier A, Shaw B, Forbes E, et al. Free smoking cessation mobile apps available in Australia: a quality review and content analysis. *Aust N Z J Public Health*. 2017 Dec;41(6):625–30.
13. Sawares AS, Shen N, Xue Y, Abi-Jaoude A, Wiljer D. The Impact of Mobile Apps on Alcohol Use Disorder: A Systematic Review Protocol. *JMIR Res Protoc*. 2017 Apr 4;6(4):e49.
14. McKay FH, Cheng C, Wright A, Shill J, Stephens H, Uccellini M. Evaluating mobile phone applications for health behaviour change: A systematic review. *J Telemed Telecare*. 2018 Jan;24(1):22–30.
15. Baskerville NB, Struik LL, Guindon GE, Norman CD, Whittaker R, Burns C, et al. Effect of a Mobile Phone Intervention on Quitting Smoking in a Young Adult Population of Smokers: Randomized Controlled Trial. *JMIR MHealth UHealth*. 2018 Oct 23;6(10):e10893.
16. BinDhim NF, McGeechan K, Trevena L. Smartphone Smoking Cessation Application (SSC App) trial: a multicountry double-blind automated randomised controlled trial of a smoking cessation decision-aid 'app'. *BMJ Open*. 2018 Jan 21;8(1):e017105.

17. Bricker JB, Mull KE, Kientz JA, Vilardaga R, Mercer LD, Akioka KJ, et al. Randomized, controlled pilot trial of a smartphone app for smoking cessation using acceptance and commitment therapy. *Drug Alcohol Depend.* 2014 Oct;143:87–94.
18. Crane D, Ubhi HK, Brown J, West R. Relative effectiveness of a full versus reduced version of the ‘Smoke Free’ mobile application for smoking cessation: an exploratory randomised controlled trial. *F1000Research.* 2019 Jan 9;7:1524.
19. Dar R. Effect of Real-Time Monitoring and Notification of Smoking Episodes on Smoking Reduction: A Pilot Study of a Novel Smoking Cessation App. *Nicotine Tob Res.* 2018 Nov 15;20(12):1515–8.
20. Garrison KA, Pal P, O’Malley SS, Pittman BP, Gueorguieva R, Rojiani R, et al. Craving to Quit: A Randomized Controlled Trial of Smartphone App–Based Mindfulness Training for Smoking Cessation. *Nicotine Tob Res* [Internet]. 2018 Jun 18 [cited 2019 Jul 4]; Available from: <https://academic.oup.com/ntr/advance-article/doi/10.1093/ntr/nty126/5039853>
21. Hassandra M, Lintunen T, Hagger MS, Heikkinen R, Vanhala M, Kettunen T. An mHealth App for Supporting Quitters to Manage Cigarette Cravings With Short Bouts of Physical Activity: A Randomized Pilot Feasibility and Acceptability Study. *JMIR MHealth UHealth.* 2017 May 26;5(5):e74.
22. Krishnan N, Elf JL, Chon S, Golub JE. COach2Quit: A Pilot Randomized Controlled Trial of a Personal Carbon Monoxide Monitor for Smoking Cessation. *Nicotine Tob Res* [Internet]. 2018 Aug 29 [cited 2019 Aug 28]; Available from: <https://academic.oup.com/ntr/advance-article/doi/10.1093/ntr/nty182/5086248>
23. Mavrot C, Wittwer S, Etter JF. Évaluation de l’application Android Stop-tabac pour téléphones portables. Université de Berne. 2017 Dec: p. 9–31.
24. O’Connor M, Whelan R, Bricker J, McHugh L. Randomized Controlled Trial of a Smartphone Application as an Adjunct to Acceptance and Commitment Therapy for Smoking Cessation. *Behav Ther* [Internet]. 2019 Jun [cited 2019 Aug 16]; Available from: <https://linkinghub.elsevier.com/retrieve/pii/S000578941930070X>
25. Peiris D, Wright L, News M, Rogers K, Redfern J, Chow C, et al. A Smartphone App to Assist Smoking Cessation Among Aboriginal Australians: Findings From a Pilot Randomized Controlled Trial. *JMIR MHealth UHealth.* 2019 Apr 2;7(4):e12745.
26. Tombor I, Beard E, Brown J, Shahab L, Michie S, West R. Randomized factorial experiment of components of the SmokeFree Baby smartphone application to aid smoking cessation in pregnancy. *Transl Behav Med.* 2019 Jul 16;9(4):583–93.
27. Bertholet N, Godinho A, Cunningham JA. Smartphone application for unhealthy alcohol use: Pilot randomized controlled trial in the general population. *Drug Alcohol Depend.* 2019 Feb;195:101–5.
28. Crane D, Garnett C, Michie S, West R, Brown J. A smartphone app to reduce excessive alcohol consumption: Identifying the effectiveness of intervention components in a factorial randomised control trial. *Sci Rep* [Internet]. 2018 Dec [cited 2019 Jul 4];8(1). Available from: <http://www.nature.com/articles/s41598-018-22420-8>
29. Gajecki M, Berman AH, Sinadinovic K, Rosendahl I, Andersson C. Mobile phone brief intervention applications for risky alcohol use among university students: a randomized controlled study. *Addict Sci Clin Pract* [Internet]. 2014 Dec [cited 2019 Jul 4];9(1). Available from: <https://ascpjournals.biomedcentral.com/articles/10.1186/1940-0640-9-11>




30. Gajecki M, Andersson C, Rosendahl I, Sinadinovic K, Fredriksson M, Berman AH. Skills Training via Smartphone App for University Students with Excessive Alcohol Consumption: a Randomized Controlled Trial. *Int J Behav Med*. 2017 Oct;24(5):778–88.
31. Glass JE, McKay JR, Gustafson DH, Kornfield R, Rathouz PJ, McTavish FM, et al. Treatment seeking as a mechanism of change in a randomized controlled trial of a mobile health intervention to support recovery from alcohol use disorders. *J Subst Abuse Treat*. 2017 Jun;77:57–66.
32. Gonzalez VM, Dulin PL. Comparison of a smartphone app for alcohol use disorders with an Internet-based intervention plus bibliotherapy: A pilot study. *J Consult Clin Psychol*. 2015 Apr;83(2):335–45.
33. Gustafson DH, McTavish FM, Chih M-Y, Atwood AK, Johnson RA, Boyle MG, et al. A Smartphone Application to Support Recovery From Alcoholism: A Randomized Clinical Trial. *JAMA Psychiatry*. 2014 May 1;71(5):566.
34. Hides L, Quinn C, Cockshaw W, Stoyanov S, Zelenko O, Johnson D, et al. Efficacy and outcomes of a mobile app targeting alcohol use in young people. *Addict Behav*. 2018 Feb;77:89–95.
35. Liang D, Han H, Du J, Zhao M, Hser Y-I. A pilot study of a smartphone application supporting recovery from drug addiction. *J Subst Abuse Treat*. 2018 May;88:51–8.
36. Hildebrandt T, Michaelides A, Mackinnon D, Greif R, DeBar L, Sysko R. Randomized controlled trial comparing smartphone assisted versus traditional guided self-help for adults with binge eating. *Int J Eat Disord*. 2017 Nov;50(11):1313–22.
37. Institute for Health Metrics and Evaluation. GBD Results Tool. Seattle, WA: IHME, University of Washington. 2016.
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders- Fifth Edition – DSM-5. Wash DC APA. 2013.
39. World Health Organization (WHO). mHealth – New horizons for health through mobile technologies. Geneva: WHO; 2011.
40. Conférence Nationale de Santé. « Faire en sorte que les Applications et Objets Connectés en santé bénéficient à tous » Avis adopté en assemblée plénière du 8 février 2018 [Internet]. 2018. Available from: [https://solidarites-sante.gouv.fr/IMG/pdf/avis\\_cns\\_aoc\\_adopt\\_plen\\_0802\\_contrib\\_cnle\\_cncph\\_220218.pdf](https://solidarites-sante.gouv.fr/IMG/pdf/avis_cns_aoc_adopt_plen_0802_contrib_cnle_cncph_220218.pdf)
41. The Office of the National Coordinator for Health Information Technology (ONC), Office of the Secretary, United States Department of Health and Human Services. Federal Health IT Strategic Plan 2015–2020 [Internet]. 2015 [cited 2019 Oct 7]. Available from: [https://www.healthit.gov/sites/default/files/9-5-federalhealthitstratplanfinal\\_0.pdf](https://www.healthit.gov/sites/default/files/9-5-federalhealthitstratplanfinal_0.pdf)
42. Berman AH, Gajecki M, Sinadinovic K, Andersson C. Mobile Interventions Targeting Risky Drinking Among University Students: A Review. *Curr Addict Rep*. 2016;3:166–74.
43. DRESS. Les jeunes, leur rapport à la santé et leur état de santé. [Internet]. 2009 2010. (L'état de santé de la population en France - Suivi des objectifs annexés à la loi de santé publique). Available from: [https://www.paca.ars.sante.fr/sites/default/files/2017-02/Dossiers\\_2009\\_2010\\_les\\_jeunes\\_leur\\_rapport\\_a\\_la\\_sante\\_et\\_leur\\_etat\\_de\\_sante.pdf](https://www.paca.ars.sante.fr/sites/default/files/2017-02/Dossiers_2009_2010_les_jeunes_leur_rapport_a_la_sante_et_leur_etat_de_sante.pdf)
44. US Department of Health and Human Services. Preventing Tobacco Use Among Youths, Surgeon General fact sheet [Internet]. HHS.gov- Office of the Surgeon General.

2017. Available from: US Department of Health and Human Services

45. Spilka S, Le Nézet O, Janssen E, Brissot A, Philippon A, Shah J, et al. Les drogues à 17 ans : analyse de l'enquête ESCAPAD 2017. OFDT. 2018 février;Tendance 123:8 p.
46. European Commission. Youth attitudes on drugs [Internet]. 2011. (N° 330). Available from: [https://ec.europa.eu/commfrontoffice/publicopinion/flash/fl\\_330\\_en.pdf](https://ec.europa.eu/commfrontoffice/publicopinion/flash/fl_330_en.pdf)
47. Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS). Report on drug use in the Americas 2015 [Internet]. Washington, D.C. 2015. Available from: [http://www.cicad.oas.org/oid/pubs/DrugUseAmericas\\_ENG\\_web.pdf](http://www.cicad.oas.org/oid/pubs/DrugUseAmericas_ENG_web.pdf)
48. Australian Institute of Health and Welfare (AIHW). National Drug Strategy Household Survey 2016: detailed findings. Canberra: AIHW. 2017; p. 168. (Drug Statistics series n° 31).
49. Rathbone AL, Clarry L, Prescott J. Assessing the Efficacy of Mobile Health Apps Using the Basic Principles of Cognitive Behavioral Therapy: Systematic Review. J Med Internet Res. 2017 Nov 28;19(11):e399.
50. Heron KE, Smyth JM. Ecological momentary interventions: Incorporating mobile technology into psychosocial and health behaviour treatments. Br J Health Psychol. 2010 Feb;15(1):1–39.
51. Research2Guidance. mHealth App Economics 2017. Current status and future trends in mobile health. MHealth Econ. 2017;1–25.
52. Petry N, Meredith S, Alessi S. Smartphone applications to reduce alcohol consumption and help patients with alcohol use disorder: a state-of-the-art review. Adv Health Care Technol. 2015 Dec;47.
53. Rajani NB, Weth D, Mastellos N, Filippidis FT. Adherence of popular smoking cessation mobile applications to evidence-based guidelines. BMC Public Health [Internet]. 2019 Dec [cited 2019 Aug 24];19(1). Available from: <https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-019-7084-7>
54. Crane D, Garnett C, Brown J, West R, Michie S. Behavior Change Techniques in Popular Alcohol Reduction Apps. J Med Internet Res. 2015 May 14;17(5):e118.
55. Payne HE, Lister C, West JH, Bernhardt JM. Behavioral Functionality of Mobile Apps in Health Interventions: A Systematic Review of the Literature. JMIR MHealth UHealth. 2015 Feb 26;3(1):e20.
56. Zhao J, Freeman B, Li M. Can Mobile Phone Apps Influence People's Health Behavior Change? An Evidence Review. J Med Internet Res. 2016 Nov 2;18(11):e287.
57. Boland VC, Stockings EA, Mattick RP, McRobbie H, Brown J, Courtney RJ. The Methodological Quality and Effectiveness of Technology-Based Smoking Cessation Interventions for Disadvantaged Groups: A Systematic Review and Meta-analysis. Nicotine Tob Res. 2018 Feb 7;20(3):276–85.
58. Whittaker R, Borland R, Bullen C, Lin RB, McRobbie H, Rodgers A. Mobile phone-based interventions for smoking cessation. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2009 [cited 2019 Jul 4]. Available from: <http://doi.wiley.com/10.1002/14651858.CD006611.pub2>

59. Moher D, Liberati A, Tetzlaff J, Altman DG, for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009 Jul 21;339(jul21 1):b2535–b2535.
60. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? *Control Clin Trials*. 1996 fév;17(1):1–12.

**Figure 1: PRISMA flowchart**



**Table 1: MESH terms used for database searching.**

<b>a. Mobile applications</b>	15) Cocaine
1) Smartphone app*	16) Opioid
2) Mobile app*	17) Gamb* 18) Binge eating
<b>b. Addiction/craving</b>	19) Porn
3) Substance use disorder	<b>c. Effectiveness</b>
4) Addict*	20) Efficacy
5) Addictive behavior	21) Effectiveness
6) Cessation	22) Impact
7) recovery	23) Validity
8) Craving	<b>d. Web-based interventions</b>
9) Alcohol	24) Web-based intervention
10) Smok*	25) Internet
11) Tobacco	
12) Cannabis	
13) Marijuana	
14) Heroin	

**Table 2:** List of applications identified by the systematic review

TOBACCO
<i>Crush the Crave</i> (15) <i>Quit Advisor Plus</i> (16) <i>SmartQuit</i> (version 1.0 et 2.1)(17,24) <i>SmokeFree</i> (18) <i>SmokeBeat</i> (19) <i>Craving to Quit</i> (20) <i>PhoS</i> (21) <i>Coach2Quit</i> (22) <i>Stop-Tabac</i> (23) <i>Can't Even Quit</i> (25) <i>SmokeFree Baby</i> (26)
ALCOHOL
<i>Alcooquizz</i> (27) <i>Drink Less</i> (28) <i>A-CHESS</i> (31,33) <i>TeleCoach</i> (30) <i>Promillekoll</i> (29) <i>Party Planner</i> (29) <i>LBMI-A</i> (32) <i>Ray's Night Out</i> (34)
ILLEGAL SUBSTANCES
<i>S-Health</i> (35)
BINGE EATING DISORDER
<i>Noom Monitor</i> (36)

**Table 3: Characteristics of controlled trials (ranged by substance/behavior)**

Authors Date & countries	Duration of study	Baseline characteristics of participants	Method	Principal results (Reduction of consumption and/or abstinence)	Impact on craving
<b>TOBACCO</b>					
<b>Baskerville et al.</b> 2018 Canada (15)	6 months	<i>N</i> = 1599  <i>Characteristics of participants:</i> daily smokers, 19 -29 years, 73% low nicotine dependence (HSI score)	RCT, superiority trial, 2 parallel groups, ITT analysis, Crush the crave (CTC) (n=820) v/s placebo app (OnRQ) (n= 779), self-reported continuous abstinence	<i>Abstinence:</i> 6-month follow-up: 7,8% for CTC v/s 9,2% for OnRQ; OR 0.83, 95% CI 0.59-1.18, p=0.30  30-day point prevalence abstinence: 14.4% for CTC v/s 16.9% for OnRQ (OR 0.82, 95% CI 0.63-1.08)  <i>Reduction of consumption:</i> Smoking less than a pack per day: Baseline: 25.7% CTC v/s 25.7% OnRQ (p=0.99) 6-month follow-up: 23.8% CTC v/s 24.4% OnRQ (p=0.86)	Not evaluated
<b>BinDhim NF, McGeechan K, Trevena L.</b> 2018 USA Australia Singapore United Kingdom (16)	6 months	<i>N</i> = 684  <i>Characteristics of participants:</i> daily smokers, ≥ 18 years. Fagerström ≤ 4 (49.6%) = 5 (13.7%) ≥ 6-10 (36.7%)	RCT, parallel group, Quit Advisor Plus (intervention) v/s placebo app (informative), self-reported continuous abstinence	<i>Abstinence:</i> 1-month follow-up: 28,5% for intervention app v/s 16,9% for informative app (RR 1.68; 95% CI 1.25-2.28).  Effect sustained at 3 months (23.8% vs 10.2%; RR 2.08; 95% CI 1.38-3.18)  and 6 months (10.2% vs 4.8%; RR 2.02; 95% CI 1.08-3.81).  <i>Reduction of consumption:</i> (not specified)	Not evaluated
<b>Bricker et al.</b> 2014 USA (17)	2 months	<i>N</i> = 196  <i>Characteristics of participants:</i> ≥ 18 years, ≥ 5 cigarettes (cig) per day,	RCT, pilot study, observational, SmartQuit (n=98) v/s QuitGuide (n=98), self-reported continuous abstinence	<i>Abstinence:</i> 2-month follow-up: 13% for SmartQuit v/s 8% for QuitGuide (OR = 2.7; 95% CI 0.8-10.3, p=0.123)	Increase in craving acceptance for SmartQuit

		not using other smoking cessation interventions.  HSI: SmartQuit: 4.9 (SD: 2.5) QuitGuide: 4.7 (SD: 2.4)		<u>Reduction of consumption:</u> (not specified)	group ( $p < 0.04$ ) only.  High acceptance of craving strongly associated to abstinence at 2-month follow up (OR 6.1; 95% CI 3.0-15.2)
<b>Crane D, Ubhi HK, Brown J, West R.</b> 2019 United Kingdom (18)	3 months	$N = 28\ 112$  <i>Characteristics of participants:</i> daily or occasional smokers, $\geq 18$ years, low to high nicotine dependence, at least 1 use of app	RCT, 1:1 parallel group, per-protocol analysis, intensive version of app (14 228) v/s minimal version (13 884), self-reported abstinence	<u>Abstinence:</u> 3-month follow-up: 19.3% for intervention group ( $n=234/1213$ ) v/s 13.8% for control group ( $n=124/901$ ) (OR: 1.50, 95% CI =1.18-1.91, $p < 0.001$ )  <u>Reduction of consumption:</u> (not specified)	Not evaluated
<b>Dar R.</b> 2018 Israel (19)	1 month	$N = 40$  <i>Characteristics of participants:</i> 18-45 years, $\geq 5$ cig per day  Fagerström: -Intervention group: (M: 12.50, SD 3.32) -Control group: (M :19.95, SD 8.56)	RCT, pilot study, intervention group ( $n=20$ ) v/s control group ('wait list') ( $n=20$ ), self-reported number of cig per day	<u>Abstinence:</u> (not specified)  <u>Reduction of consumption:</u> Significant decline in smoking rate at 30 day-trial ( $p < 0.001$ ) for intervention group only	Not evaluated
<b>Garrison et al.</b> 2018 USA (20)	6 months	$N = 505$  <i>Characteristics of participants:</i> 18–65 years, (mean) 16 cig per day, $\leq 3$ months abstinence the previous year	RCT, ITT, parallel group: MMT-ES ( $n=245$ ) v/s ES ( $n=260$ ), survey at 1, 3 and 6 months. Smokerlyzer breath CO monitor. Measurement of craving by CEQ.	<u>Abstinence:</u> 6-month follow-up: (mean) quit rate 11.1%, no significant difference between the groups (MMT-ES, 9.8%; ES, 12.1%; $\chi^2(1) = 0.43$ , $p = .51$ ).  <u>Reduction of consumption:</u> At 6 months: significant decrease in number of	Association between craving and smoking reduced in the MMT-ES group throughout



				cig per day ( $p < 0.0001$ ), of craving intensity ( $p < 0.0001$ ), of craving frequency ( $p < 0.0001$ ) and increase in mindfulness ( $p < 0.05$ ), similar in both groups	the trial v/s ES.
<b>Hassandra et al.</b> 2017 Finland (21)	6 months	$N = 44$  <i>Characteristics of participants:</i> 18-65 years, $\geq 10$ cig per day, no psychiatric comorbidity or other addictions	RCT, pilot trial, 3 weeks behavioral counselling program on benefits of physical activities, additional aid to quit, 3-7 days after quit date: training on relapse prevention and craving management. Intervention group ( $n=25$ ) (app + BCT) v/s control group ( $n=19$ ) (BCT only), self-reported abstinence	<u>Abstinence:</u> No significant decrease in quit rate between the two groups (36% intervention group ( $n=16/44$ ) v/s 32% control group ( $n=14/44$ ))  <u>Reduction of consumption:</u> (not specified)	No significant decrease in number of relapse or craving.
<b>Krishnan N, Elf JL, Chon S, Golub JE.</b> 2018 USA (22)	1 month	$N = 102$  <i>Characteristics of participants:</i> daily smokers, $\geq 18$ years.  Nicotine dependence not specified	RCT, pilot trial, 1 :1, brief intervention (BI) + CO-monitoring+ Coach2Quit v/s BI only, Biochemical verification of carbon monoxide (CO) level (breath and urine test) of cessation	<u>Abstinence:</u> At 1 month: 1 participant quit in each arm  <u>Reduction of consumption:</u> CO level and number of cig per day similar in both groups [(intervention: $-3.0$ [interquartile range (IQR) $-12.0, 2.0$ ] control: $-2.5$ [IQR $-9.0, 2.0$ ] et (intervention: $-5.5$ [IQR $-14.0, -1.0$ ]; control: $-6.0$ [IQR $-10.0, -2.0$ ]), respectively].	Not evaluated
<b>Mavrot C, Wittwer S, Etter JF.</b> 2017 Switzerland (23)	6 months	$N = 2892$  <i>Characteristics of participants:</i> daily or ex-smokers, $\geq 18$ years, (mean) 16 cig per day, 15 minutes after waking up	RCT, ITT, 1 :1 parallel group, intervention group ( $n=1449$ ) v/s control group ( $n=1443$ ) (placebo app), self-reported number of cig per day, time before first cig	<u>Abstinence:</u> At 3 months: 16.2% intervention group v/s 15.7% control group, OR=1.04; 95% CI [0.85-1.28], $p = 0.685$ . At 6 months: 11.9% intervention group v/s 12.2% control group, OR= 0.97 CI [0.77- 1.22], $p = 0.819$ .  Quit rate among ex-smokers similar in both arms at baseline.  <u>Reduction of consumption:</u> (not specified)	Not evaluated
<b>O'Connor M, Whelan R,</b>	6 months	$N = 150$	RCT, ITT, 3-arm parallel	<u>Abstinence:</u>	Not

<b>Bricker J, McHugh L.</b> 2019 Ireland (24)		<i>Characteristics of participants:</i> ≥ 18 years, ≥ 10 cig per day since at least 1 year, no medication  Fagerström: 4.7	groups: Combined group (Smartquit + 'ACT') (n=50) v/s 'ACT' group (n=50) v/s BCT group (n=50). 6 weeks and 90 min sessions of 'ACT' and BCT Biochemical verification of abstinence at 6 weeks and 6 months	At 6 weeks: 36% combined group v/s 20% 'ACT' group v/s 24% BCT group (p> 0.05) At 6 months: 24% combined group v/s 24% 'ACT' group v/s 20% BCT group (p> 0.05)  <u>Reduction of consumption:</u> Significant decrease for 'SmartQuit' group at 6 weeks but not at 6 months	evaluated
<b>Peiris et al.</b> 2019 Australia (25)	6 months	N= 49  <i>Characteristics of participants:</i> aboriginal smokers > 16 years Nicotine dependence not specified	RCT, pilot trial, 1 :1, intervention group (app) (n=25) v/s control group (usual treatment) (n=24), carbon monoxide breath test	<u>Abstinence:</u> At 6 months: 4.5% (n=1/22) intervention group v/s 0% (n=0/24) control group.  <u>Reduction of consumption:</u> (not specified)	Not evaluated
<b>Tombor et al.</b> 2018 United Kingdom (26)	1 month	N= 565  <i>Characteristics of participants:</i> pregnant smokers, ≥18 years, smoke at least once per week Medium nicotine dependence (HSI: 2.5)	RCT, factorial design (2x2x2x2x2), evaluation of 5 modules in each arm: intervention group (complete version) v/s control group (minimal version), self-reported number of smoke-free days	<u>Abstinence:</u> (not specified)  <u>Reduction of consumption:</u> No significant effect of the 5 modules on use	Not evaluated
<b>ALCOHOL</b>					
<b>Bertholet N, Godinho A, Cunningham JA.</b> 2018 Canada Switzerland (27)	6 months	N= 977  <i>Characteristics of participants:</i> ≥18ans, AUDIT≥8, ≥15 drinks per week  AUDIT: (M: 18.3, SD: 7.1)	RCT, multicentric, 1 :1 parallel group, intervention group (n=461) v/s control group (n=516), simple blind, ITT analysis, self-reported number of drinks	<u>Abstinence:</u> (not specified)  <u>Reduction of consumption:</u> Number of drinks per week: Baseline: 28.9 (SD: 16.7) in both arms 6-month follow-up: 18.9 (SD: 15.0) intervention group v/s 21.4 (SD: 18.0) control group (IRR 0.93, 95% CI 0.84-1.03, p=0.17)  No significant decrease on number of drinks on one occasion (IRR 0.99, 95% CI 0.93-1.06, p=0.81)	Not evaluated
<b>Crane D, Garnett C, Michie S, West R, Brown J.</b> 2018	2 months	N= 672  <i>Characteristics of participants:</i> excessive	RCT, randomized block design, full version (n=336) v/s minimal version(n=336) of app,	<u>Abstinence:</u> (not specified)  <u>Reduction of consumption:</u> Reduction in number of drinks per week and	Not evaluated

United Kingdom (28)		drinkers, ≥18years, AUDIT (M: 19.1, SD: 6.56) willing to quit	ITT, self-reported number of drinks per week and AUDIT score	AUDIT score more important for full version but non-significant at 2-month follow-up	
<b>Gajecki M, Andersson C, Rosendahl I, Sinadinovic K, Fredriksson M, Berman AH.</b> 2017 Sweden (30)	3 months	<i>N= 186</i>  <i>Characteristics of participants:</i> university students with excessive consumption, AUDIT (M: 10.7, SD: 3.9), quantity: 9.3 drinks/week	RCT, 3-arm study : intervention group (n=93) v/s 'wait list' group (access to app after 6 weeks)(n=93), compared to control group of another trial (29), assessment by DDQ and AUDIT	<u><i>Abstinence:</i></u> (not specified)  <u><i>Reduction of consumption:</i></u> - Decrease of excessive alcohol consumption in intervention group (45.3%) v/s 'wait list' group (50%) v/s control group (72.7%) at 6 weeks, not maintained at 12 weeks - Decrease in quantity of drinks for intervention group only (-4.76, 95% CI [- 6.67, -2.85], Z = -2.09, p = 0.037), at 6 weeks, not maintained at 12 weeks - Decrease in drinking frequency (-0.83, 95% CI [-1.14, -0.52], Z = -2.04, p = 0.041) at 6 and 12 weeks.	Not evaluated
<b>Gajecki M, Berman AH, Sinadinovic K, Rosendahl I, Andersson C.</b> 2014 Sweden (29)	7 weeks	<i>N= 1932</i>  <i>Characteristics of participants:</i> university students, hazardous drinking, AUDIT: (M: 14,08, SD: 5,00), quantity: 17 drinks/week, frequency: 3,5/week, binge drinking: 1,87/week.	RCT, 3-arm study, 1 :1 :1, per-protocol analysis, Promillekoll group (n= 643) v/s PartyPlanner group (n=640) v/s control group(n=649), assessment by DDQ, AUDIT and eBAC	<u><i>Abstinence:</i></u> (not specified)  <u><i>Reduction of consumption:</i></u> No impact on consumption in any of the groups. Per-protocol analysis show an increase in drinking frequency for Promillekoll app compared to control group (p=0.001)	Not evaluated
<b>Glass et al.</b> 2017 USA (31)	12 months	<i>N= 349</i>  <i>Characteristics of participants:</i> Patients ≥18 years, alcohol use disorder (DSM 4), discharge from 5 residential treatment programs	RCT, cause and effect study, recruitment 2 weeks before discharge, outpatient addiction treatment + A-CHESS v/s mutual help + A-CHESS, access to app during 8 months, surveys by telephone at 4, 8 and 12 months, self-reported consumption	<u><i>Abstinence:</i></u> An increase in abstinence was observed in both group with no mediation effect of A-CHESS  <u><i>Reduction of consumption:</i></u> A decrease in the number of risky drinking days was observed in both groups. A causal relationship with A-CHESS was found in the outpatient addiction treatment group.  The A-CHESS group had increased odds of obtaining outpatient addiction treatment (OR = 2.14; 95% IC [1.27–3.61]).	Not evaluated
<b>Gonzalez VM, Dulin PL.</b>	6 weeks	<i>N=54</i>	Controlled pilot trial, not randomized, 'LBMI-A'	<u><i>Abstinence:</i></u> Significant increase in quit rate for LBMI-A	Not evaluated

2015 USA (32)		<p><i>Characteristics of participants:</i> 18-45 years, alcohol use disorder (DSM5)</p> <p>SADQ: LBMI-A: (M:13,82, SD 6,51)&gt;&gt; low severity Placebo app + bibliography: (M: 16,50, SD: 6,52)&gt;&gt; medium severity</p>	(n=28) v/s placebo app + bibliography (n=26), self-reported consumption	<p>group compared to the control group</p> <p><u>Reduction of consumption:</u> Significant decrease in number of drinks per week as well as binge drinking in both groups</p>	
<b>Gustafson DH, McTavish FM, Chih M et al.</b> 2014 USA (33)	12 months	<p>N= 349</p> <p><i>Characteristics of participants:</i> Patients ≥18ans, alcohol use disorder (DSM 4), enrolled in 5 residential programs (BCT, motivational intervention, psychoeducation), no psychiatric comorbidities</p>	RCT, parallel group 1 :1, randomized block design, intervention group (usual treatment + A-CHESS) (n=170) v/s control group (usual treatment only) (n=179), self-reported consumption	<p><u>Abstinence:</u> Significant increase in quit rate at follow-up compared to control group (51,9% v/s 39,6%; p = 0.03)</p> <p><u>Reduction of consumption:</u> Signification decrease in number of days of risky drinking in intervention group compared to control group (M =1.39 days v/s 2.75 days respectively; p= 0.003; 95% CI [0.46–2.27]).</p>	Not evaluated
<b>Hides et al.</b> 2018 Australia (34)	6 months	<p>N= 197</p> <p><i>Characteristics of participants:</i> young adults, 16-25 years, hazardous drinking, &gt; 4 drinks/ occasion during the last month, AUDIT &gt; 7 (45.1%)</p>	RCT, immediate access to app v/s differed access (1 month), assessment by AUDIT score	<p><u>Abstinence:</u> (not specified)</p> <p><u>Reduction of consumption:</u> Increase in knowledge at 1 month without consequence on use (p &lt; 0.001, d = 0.46)</p> <p>Decrease in quantity of consumption at 6 months, mainly among men with problematic used</p>	Not evaluated
<b>ILLEGAL SUBSTANCES</b>					
<b>Liang D, Han H, Du J, Zhao M, Hser YI.</b> 2018 China (35)	1 month	<p>N= 75</p> <p><i>Characteristics of participants:</i> Adult, use of heroin or other substances during the last month, methadone maintenance treatment</p>	<p>RCT, S-Health (n=50) v/s control group (SMS only) (n=25), self-reported consumption et urine test*</p> <p>*<i>morphine, methamphetamine, ketamine, marijuana</i></p>	<p>26.2% v/s 50% of positive urine test in the intervention and control group respectively (p=0.06)</p> <p>Decrease in number of days of consumption the previous week: intervention group (M=0.71, SD= 1.87) v/s control group (M= 2.20, SD 3.06) (p &lt; 0.05)</p>	Not evaluated

BINGE EATING DISORDER					
Hildebrandt et al. 2017 USA (36)	6 months	N= 66  <i>Characteristics of participants: ≥ 18 years, diagnosis of bulimia nervosa or BED, DSM 5 or DMS IV with once weekly binge eating and/or purging</i>	RCT, ITT, Noom monitor + BCT (self-help guide) v/s BCT only, assessment by EDE-Q	No significant decrease in eating disorder behavior at 6 months.  Decrease in compensatory behavior similar in both groups at follow-up	Not evaluated

*ACT, acceptance and commitment therapy; app, application; AUDIT, alcohol use disorders test; BCT, behavioral cognitive therapy; CEQ, craving experience questionnaire; CI, confidence interval; cig, cigarettes; DDQ, daily drinking questionnaire; eBAC, estimated blood alcohol concentration; EDE-Q, eating disorder examination questionnaire; ES, experience sampling; HSI, heaviness smoking index; IRR, incidence rate ratio; ITT, intention-to-treat; M, mean; MMT-ES, mindfulness training-experience sampling; OR, odd ratio; RCT, randomized controlled trial; RR, relative risk; SD, standard deviation.*

**Table 4: Characteristics of interventional and control groups (ranged by substance/behavior).**

Authors	Name of application Functionalities/specificities	Control group(s) Functionalities
<b>TOBACCO</b>		
<b>Baskerville et al.</b> (15)	<p>App: <u>Crush the Crave</u> (CTC) version 2.1</p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Information: relapse, craving, medications</li> <li>- Set quit date and help to choose the quit mode,</li> <li>- Track money saved, health benefits and number of cig per day</li> </ul> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Positive reinforcement: motivational message, virtual rewards</li> <li>- Identify cues and help to manage craving (web-based distractions)</li> </ul>	<p><u>On the Road to Quitting (OnRQ)</u></p> <ul style="list-style-type: none"> <li>- Self-help guide,</li> <li>- Informative,</li> <li>- Similar contents to CTC</li> </ul>
<b>BinDhim NF, McGeechan K, Trevena L.</b> (16)	<p>App: <u>Quit Advisor Plus</u></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Information: quitting options (benefits/risks)</li> <li>- Quitting agenda</li> <li>- Quitting benefits tracker</li> </ul> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Decision-aid app to help choose quit method</li> <li>- Mandatory information</li> <li>- Customized, systematic and daily motivational messages</li> </ul>	<p><u>Placebo app:</u></p> <ul style="list-style-type: none"> <li>- Non-mandatory information on quit methods</li> <li>- No structured information on benefits/harms of different quit methods</li> </ul>
<b>Bricker et al.</b> (17)	<p>App: <u>SmartQuit</u> version 1.0</p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Information on medications</li> <li>- Motivational messages on reasons to quit</li> <li>- Customized quit plan (treatments, social support)</li> <li>- Tips on craving managements</li> </ul> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Craving management based on acceptance and commitment therapy.</li> <li>- Track number of craving passed without smoking</li> </ul>	<p><u>QuitGuide app:</u></p> <ul style="list-style-type: none"> <li>- Based on US guidelines</li> <li>- Information on medications</li> <li>- Motivates to quit</li> <li>- Personalized quit plan</li> <li>- Craving management strategies</li> </ul>
<b>Crane D, Ubhi HK, Brown J, West R.</b> (18)	<p>App: <u>SmokeFree</u></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Information on benefits of quitting</li> <li>- Track progress: number of days without smoking, savings</li> </ul> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Daily missions on craving prevention and management, based on behavioral cognitive therapy.</li> <li>- Virtual rewards</li> </ul>	<p><u>Placebo app:</u></p> <ul style="list-style-type: none"> <li>- Minimal version</li> <li>- Excluded missions</li> </ul>

<b>Dar R.</b> (19)	<p><i>App: <u>SmokeBeat</u></i></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Monitoring: detected hand to mouth movements predicting smoking, number of cig per day</li> </ul> <p><i>Specificities:</i> (‘smart Watch’ or connected bracelets)</p> <ul style="list-style-type: none"> <li>- Real-time identification of smoking</li> </ul>	<p><u>‘Wait list’ group:</u></p> <ul style="list-style-type: none"> <li>- No intervention</li> </ul>
<b>Garrison et al.</b> (20)	<p><i>App: <u>Craving to quit</u></i></p> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Mindfulness training</li> <li>- Meditation techniques</li> <li>- Conscience of craving (RAIN: Recognize, Accept, Investigate and Note)</li> </ul>	<p><u>Placebo app:</u></p> <ul style="list-style-type: none"> <li>- Minimal version</li> <li>- ‘Experience sampling/ES’: monitoring of use and real-time craving</li> </ul>
<b>Hassandra et al.</b> (21)	<p><i>App: <u>PhoS</u> (Physical activity over smoking)</i></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Information on risks of smoking</li> <li>- Motivational messages to quit</li> </ul> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Craving management by physical exercises</li> </ul>	<p><u>Usual treatment:</u></p> <ul style="list-style-type: none"> <li>- Behavioral cognitive therapy</li> </ul>
<b>Krishnan N, Elf JL, Chon S, Golub JE.</b> (22)	<p><i>App: <u>Coach2Quit</u></i></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Measurement of exhaled CO (eCO) twice per day (automatic reminder)</li> <li>- Information on consumption based on eCO</li> </ul>	<p><u>Usual treatment:</u></p> <ul style="list-style-type: none"> <li>- Brief intervention</li> </ul>
<b>Mavrot C, Wittwer S, Etter JF.</b> (23)	<p><i>App: <u>Stop-Tabac</u></i></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Customized tracker: consumption, savings, progress</li> <li>- Interactive coach: personalized messages on abstinence, craving, high risk situations</li> <li>- Help to manage craving: messages (SMS) and counselling on relapse prevention, relaxation exercises</li> <li>- Professional help through quitline/forum</li> </ul> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Customization</li> <li>- Systematic and automatic messages at degressive frequency (except for relapse)</li> </ul>	<p><u>Placebo app:</u></p> <ul style="list-style-type: none"> <li>- Consumption tracker</li> <li>- Few impersonalized messages.</li> </ul>
<b>O’Connor M, Whelan R, Bricker J, McHugh L.</b> (24)	<p><i>App: <u>SmartQuit version 2.1 (2Morrow)</u></i></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Personalized quit plan</li> <li>- Determine reasons to quit</li> </ul> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Based on acceptance and commitment therapy (ACT)</li> </ul>	<p><u>Control group 1:</u></p> <ul style="list-style-type: none"> <li>- Face to face ACT</li> </ul> <p><u>Control group 2</u></p> <ul style="list-style-type: none"> <li>- Behavioral cognitive therapy</li> </ul>

	<ul style="list-style-type: none"> <li>- Track craving passed without smoking</li> <li>- Combined to face to face ACT</li> </ul>	
<b>Peiris et al.</b> (25)	<p><i>App: <u>Can't Even Quit</u></i></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Automated motivational messages (frequency established by user) on abstinence and relapse prevention while experiencing craving</li> <li>- Consumption tracker</li> </ul>	<p><u>Control group:</u></p> <ul style="list-style-type: none"> <li>- No intervention</li> <li>- Participants encouraged to use smoking cessation support</li> </ul>
<b>Tombor et al.</b> (26)	<p><i>App: <u>SmokeFree Baby</u></i></p> <p><i>Functionalities:</i> 5 modules:</p> <ol style="list-style-type: none"> <li>1) <u>Identity</u>: persuasion and modulation of self-image (positive image, accepting his identity as ex-smoker)</li> <li>2) <u>Stress management</u>: information on tobacco and stress, stress management techniques, relaxation exercises</li> <li>3) <u>Effects on health</u>: information on harms of smoking and benefits to quit</li> <li>4) <u>Face to face</u>: social support</li> <li>5) <u>Behavior</u>: encourage behavior change, alternative solutions to smoking</li> </ol>	<p><u>Placebo app:</u></p> <ul style="list-style-type: none"> <li>- Few tips on cessation</li> <li>- Non-interactive</li> </ul>
<b>ALCOHOL</b>		
<b>Bertholet N, Godinho A, Cunningham JA.</b> (27)	<p><i>App: <u>Alcooquizz</u></i></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Information on use and its consequences</li> <li>- Monitoring of consumption</li> <li>- Tool to design a driver</li> </ul> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Not automated (app use depends on user)</li> <li>- Reinforcement of self-efficacy (fix personal objectives)</li> <li>- Customized normative feedback</li> <li>- eBAC calculation</li> </ul>	<p><u>Control group:</u></p> <ul style="list-style-type: none"> <li>- No intervention</li> </ul>
<b>Crane D, Garnett C, Michie S, West R, Brown J.</b> (28)	<p><i>App: <u>Drink Less</u></i></p> <p><i>Functionalities:</i> (5 interventional module)</p> <ol style="list-style-type: none"> <li>1) Customized normative feedback</li> <li>2) Cognitive bias retraining</li> <li>3) Self-affirmation: identity change</li> <li>4) Action planning</li> <li>5) Self-monitoring of consumption and harms</li> </ol>	<p><u>Placebo application:</u></p> <ul style="list-style-type: none"> <li>- Minimal version</li> <li>- Informative</li> <li>- Not personalized</li> </ul>
<b>Gajecki M, Andersson C, Rosendahl I, Sinadinovic K, Fredriksson M, Berman AH.</b> (30)	<p><i>App: <u>TeleCoach</u></i></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Information on consequences of hazardous drinking</li> <li>- Monitoring of number of drinks/days</li> </ul> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Relapse prevention skills training: <ol style="list-style-type: none"> <li>1) « Say No to Alcohol »: analysis of high risks situations, refusal exercise: “say no to alcohol”</li> <li>2) « Feel better without alcohol »:</li> </ol> </li> </ul>	<p><u>Control group 1:</u></p> <ul style="list-style-type: none"> <li>- Access to app after 6 weeks</li> </ul> <p><u>Control group 2 (29):</u></p> <ul style="list-style-type: none"> <li>- No intervention</li> </ul>



	relaxation exercises, positive thinking, urge surfing training	
<b>Gajecki M, Berman AH, Sinadinovic K, Rosendahl I, Andersson C.</b> (29)	<p><i>App:</i> 1) <u>Promillekoll</u> 2) <u>PartyPlanner</u></p> <p><i>Functionalities:</i> <u>Promillekoll:</u></p> <ul style="list-style-type: none"> <li>- Real-time monitoring of number of drinks and eBAC calculation</li> <li>- Specific strategies to maintain eBAC below 0.06% to prevent dangerous drinking</li> <li>- Information on use and eBAC</li> </ul> <p><u>PartyPlanner</u></p> <ul style="list-style-type: none"> <li>- Simulate and plan use before an event; compared to real consumption afterwards</li> <li>- Monitoring of number of drinking and eBAC calculation</li> </ul>	<p><u>Control group:</u></p> <ul style="list-style-type: none"> <li>- No intervention</li> </ul>
<b>Glass et al.</b> (31)	<p><i>App:</i> <u>A-CHESS</u></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Information on addiction</li> <li>- Motivational messages</li> <li>- Monitoring of drinks</li> <li>- Interaction with other drinkers and experts</li> <li>- Testimony of patients and families</li> </ul> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Identify high risk situations (GPS)</li> <li>- Craving management by behavioral cognitive therapy</li> <li>- Customization</li> <li>- Combined to outpatient addiction treatment</li> </ul>	<p><u>Mutual help:</u></p> <ul style="list-style-type: none"> <li>- associated to A-CHESS</li> </ul>
<b>Gonzalez VM, Dulin PL.</b> (32)	<p><i>App:</i> <u>LBMI-A</u></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- 7 psycho-educative modules</li> </ul> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Based on real-time assessment and intervention</li> <li>- Real-time monitoring of craving (intensity, cues)</li> <li>- Real-time solutions to manage craving</li> </ul>	<p><u>Control group:</u></p> <ul style="list-style-type: none"> <li>- Placebo app: Brief intervention during 1 hour on internet on behavior change</li> <li>- + bibliography: documents on craving management, how to refuse drinking and overcome relapse</li> </ul>
<b>Gustafson DH, McTavish FM, Chih M et al.</b> (33)	<p><i>App:</i> <u>A-CHESS</u></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Information on addiction</li> <li>- Motivational messages</li> <li>- Monitoring of drinks</li> <li>- Interaction with other drinkers and experts</li> <li>- Testimony of patients and families</li> </ul> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Identify high risk situations (geolocation)</li> <li>- Craving management by behavioral cognitive therapy</li> </ul>	<p><u>Usual treatment:</u></p> <ul style="list-style-type: none"> <li>- Medications</li> <li>- Behavioral cognitive therapy</li> </ul>

	- Customization	
<b>Hides et al.</b> (34)	<p>App: <u>Ray's Night Out</u></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Information, motivation and technics to maintain consumption goals</li> <li>- Information about how to reduce risks of intoxication</li> <li>- Information on physical and behavioral consequences of intoxication</li> <li>- Monitoring of number of drinks per event</li> </ul>	<p><u>'wait list' group:</u></p> <ul style="list-style-type: none"> <li>- Differed access to app at 1 month</li> </ul>
<b>ILLEGAL SUBSTANCES</b>		
<b>Liang D, Han H, Du J, Zhao M, Hser YI.</b> (35)	<p>App: <u>S-Health</u></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Information on risks reduction (text message at predefined time)</li> <li>- Customized motivational messages on positive/negative affects</li> </ul> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Daily surveys (predefined time/ upon request) on <ol style="list-style-type: none"> <li>1) craving intensity,</li> <li>2) affects,</li> <li>3) cues (emotions, place, context),</li> <li>4) responses to stimuli,</li> <li>5) social context (alone or with a particular person)</li> </ol> </li> <li>- Personalization</li> </ul>	<p><u>Placebo app:</u></p> <ul style="list-style-type: none"> <li>- Few informative messages</li> </ul>
<b>BINGE EATING DISORDER</b>		
<b>Hildebrandt et al.</b> (36)	<p>App: <u>Noom monitor</u></p> <p><i>Functionalities:</i></p> <ul style="list-style-type: none"> <li>- Self-monitoring: exercise, meal/snacks, compensatory behaviors, craving, weight</li> <li>- Personal notes</li> </ul> <p><i>Specificities:</i></p> <ul style="list-style-type: none"> <li>- Combined use with behavioral cognitive therapy (self-help guide)</li> </ul>	<p><u>Control group:</u></p> <ul style="list-style-type: none"> <li>- Behavioral cognitive therapy only</li> </ul>

app, application; cig, cigarettes; eBAC, estimated blood alcohol concentration; US, United States (of America).

**Table 5: Bias risk assessment- JADAD score (ranged by substance/behavior)**

Authors Application	Randomization?	Appropriate randomization?	Double blind?	Appropriate method of double-blinding?	Withdrawal/drop-outs described?	Total
<b>TOBACCO</b>						
<b>Baskerville NB et al.</b> (Crush the Crave) (15)	Yes	Yes	Yes	Yes	Yes	5
<b>BinDhim NF, McGeechan K, Trevena L.</b> (Quit Advisor Plus) (16)	Yes	Yes	Yes	Yes	No	4
<b>Bricker et al.</b> (SmartQuit 1.0) (17)	Yes	Yes	Yes	No (not described)	Yes	3
<b>Crane D, Ubhi HK, Brown J, West R.</b> (SmokeFree) (18)	Yes	Yes	No	-	Yes	3
<b>Dar R.</b> (SmokeBeat) (19)	Yes	No	No	-	No	0
<b>Garrison KA et al.</b> (Craving to Quit) (20)	Yes	No (not described)	Yes	Yes	Yes	3
<b>Hassandra et al.</b> (PhoS) (21)	Yes	Yes	Yes	Yes	Yes	5
<b>Krishnan N, Elf JL, Chon S, Golub JE.</b> (Coach2Quit) (22)	Yes	No (not described)	Yes	No (not described)	Yes	1
<b>Mavrot C, Wittwer S, Etter JF.</b> (Stop-Tabac) (23)	Yes	Yes	No	-	Yes	3
<b>O'Connor M, Whelan R,</b>	Yes	Yes	No	-	Yes	3

<b>Bricker J, McHugh L.</b> (SmartQuit 2.1/ 2Morrow) (24)						
<b>Peiris et al.</b> (Can't Even Quit) (25)	Yes	Yes	Yes	No (not described)	Yes	3
<b>Tombor et al.</b> (SmokeFree Baby) (26)	Yes	Yes	No	-	Yes	3
<b>ALCOHOL</b>						
<b>Bertholet N, Godinho A, Cunningham JA.</b> (Alcooquizz) (27)	Yes	Yes	No	-	No	2
<b>Crane D, Garnett C, Michie S, West R, Brown J.</b> (DrinkLess) (28)	Yes	Yes	No	-	No	2
<b>Gajecki M, Andersson C, Rosendahl I, Sinadinovic K, Fredriksson M, Berman AH.</b> (TeleCoach) (30)	Yes	Yes	No	-	Yes	3
<b>Gajecki M, Berman AH, Sinadinovic K, Rosendahl I, Andersson C.</b> (Promillekoll/PartyPlanner) (29)	Yes	Yes	No	-	Yes	3
<b>Glass et al.</b> (A-CHESS) (31)	Yes	Yes	No	-	Yes	3
<b>Gonzalez VM, Dulin PL.</b> (LBMI-A) (32)	No	-	No	-	Yes	1
<b>Gustafson DH, McTavish FM, Chih M et al.</b> (A-CHESS) (33)	Yes	Yes	No	-	Yes	3

<b>Hides et al.</b> (Ray's Night Out) (34)	Yes	Yes	No	-	Yes	3
<b>ILLEGAL SUBSTANCES</b>						
<b>Liang D, Han H, Du J, Zhao M, Hser YI.</b> (S-Health) (35)	Yes	No	No	-	Yes	1
<b>BINGE EATING DISORDER</b>						
<b>Hildebrandt et al.</b> (Noom monitor) (36)	Yes	Yes	No	-	Yes	3

**Table 6: Studies in progress or waiting for publication on Clinical Trial****Tobacco**

	<b>Titles</b>	<b>Applications</b>	<b>Identifications</b>
1)	Developing a Smartphone App with Mindfulness Training for Teen Smoking Cessation	Craving to Quit (C2Q Teen app)	NCT02218281
2)	Automated Mobile Contingency Management for Smoking Cessation: a Pilot RCT	<i>Not specified</i>	NCT03739437
3)	Efficacy of a smoking cessation intervention using smartphones	SmokeFree Buddy	ISRCTN11154315
4)	Just Kwit: mobile intervention for Tobacco Cessation	JustKwit	NCT03538678
5)	Smoking Cessation Smartphone App for Cancer Patients (Quit2Heal Study)	Quit2Heal	NCT03600038
6)	Impact of a smartphone application on smoking cessation: a randomized controlled trial	Stop-Tabac	ISRCTN11318024
7)	Study of effectiveness of a smartphone application for quitting smoking	BupaQuit	ISRCTN10548241
8)	Mindfulness Based Smoking Cessation Among Cancer Survivors	Craving to Quit	NCT04038255

**Alcohol**

	<b>Titles</b>	<b>Applications</b>	<b>Identifications</b>
1)	The Efficacy of a Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients	<i>Not specified</i>	NCT02385643
2)	The Effectiveness of a Smartphone Application in the Treatment of Alcohol Used Disorder	UControlDrink	NCT03396887
3)	Project Guard: reducing Alcohol Misuse/Abuse in the National Guard	SP-BI	NCT02860442

**Eating disorder**

	<b>Titles</b>	<b>Applications</b>	<b>Identifications</b>
1)	Augmenting Specialty Eating Disorder Clinical Treatment With a Smartphone Application	Recovery record	NCT02484794

**Cannabis**

	<b>Titles</b>	<b>Applications</b>	<b>Identifications</b>
1)	A randomized controlled trial of a smartphone application for people wanting to reduce or quit their use of cannabis	Joint Control	ACTRN12616000622404

## **Serment Hippocrate**

*"Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité. Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux. Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité. J'informerai les patients des décisions envisagées, de leurs raisons et de leurs conséquences. Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences. Je donnerai mes soins à l'indigent et à quiconque me les demandera. Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire. Admise dans l'intimité des personnes, je tairai les secrets qui me sont confiés. Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les mœurs. Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément. Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission. Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés. J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité. Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonorée et méprisée si j'y manque.*

## **Résumé**

**Contexte** : Moins de 20% des personnes, atteintes de pathologies addictives, ont accès à un traitement adapté. La santé mobile peut contribuer à améliorer l'accès aux soins. Aucune revue systématique n'évalue l'efficacité des applications mobiles de santé.

**Objectifs** : Décrire les essais cliniques contrôlés qui évaluent l'efficacité des applications smartphones ciblant les troubles de l'usage, comprendre les stratégies de changement de comportement utilisées et la prise en compte du craving.

**Méthode** : Une revue systématique a été effectuée sur MEDLINE, CENTRAL et PsycINFO.

**Résultats** : Les 22 articles retenus, publiés entre 2014 et 2019, correspondaient à 22 applications prenant en charge le tabac, l'alcool, les substances illégales et l'accès hyperphagique. Le groupe témoin avait accès aux traitements habituels ou une application 'placebo' ou aucune intervention. Huit applications ont montré un impact positif sur le changement du comportement d'usage. La majorité des applications informait sur les risques de la consommation et proposait une surveillance. Douze applications prenaient en compte le craving.

**Discussion** : Les résultats sont limités par d'important biais dont l'hétérogénéité des groupes contrôles. La durée des études était trop courte pour prédire la pérennité des résultats. L'impact positif sur le craving semble être lié à une diminution de l'usage.

**Conclusion** : Les preuves sont insuffisantes pour pouvoir recommander l'utilisation des applications smartphones dans la pratique médicale. La prise en compte plus systématique du craving, indépendamment du comportement d'usage, devrait être envisagée pour prévenir les risques de rechutes. Des évaluations à plus long terme seront nécessaires pour préciser la durabilité du changement de comportement d'usage.

**Mots-clés** : trouble de l'usage, m-santé, efficacité, applications mobiles, revue systématique.